Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
JAK3 protein kinase inhibitor CP 690550, 2 mg  

JAK3 protein kinase inhibitor CP 690550, 2 mg

3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile

Synonyms: Tasocitinib, Tofacitinib
CP 690550 is a Janus Kinase 3 (JAK3) inhibitor.

More details

PKI-CP690-002

Availability: within 3 days

104,00 €

Background: CP 690550 is a Janus Kinase 3 (JAK3) inhibitor with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.  CP 690550 / Tasocitinib / Tofacitinib is an immunosuppressive agent exhibiting potent effects in preclinical transplantation and arthritis models; clinically safe and effective in preventing transplant rejection and improving symptoms of rheumatoid arthritis and psoriasis.
This product is also available as its citrate salt form, Tofacitinib citrate.

Chemical formula: C16H20N6O
Molecular weight: 312.37 g/mol
Purity: 99 %
Appearance: White solid
Solubility: Soluble in 0.1N HCl(aq) and DMSO
CAS Number: 477600-75-2

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  

References

AC Papageorgiou and LEK Wikman, Is JAK3 a new drug target for immunomodulation-based therapies? Trends Pharmacol. Sci. 2004, 25(11), 558-562.
 
E Kudlacz et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am. J. Transplant. 2004, 4(1), 51-7.
 
E Kudlacz et al. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur. J. Pharmacol. 2008, 582(1-3), 154-61.
 
PS Changelian et al. Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor. Sci. 2003, 302(5646), 875-878.